Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, Herrera-Gomar M, Zamora-Valdés D, Uribe M

Language: English
References: 23
Page: 164-166
PDF size: 41.98 Kb.

Text Extraction

Acute liver failure is a clinical condition associated with high mortality despite recent technological advances. Supportive devices such as the Molecular Adsorbents Recirculating System (MARS®) provide therapeutic strategies to add time to find an organ for orthotopic liver transplantation or to allow the native liver to recover sufficiently to make transplantation unnecessary. In this series of cases, we discuss our initial experiences with three patients with acute liver failure. One patient had high bilirubin levels caused by Epstein–Barr virus infection and responded well after three MARS sessions. In a second patient, MARS therapy was used to treat acute-on-chronic liver failure caused by chronic hepatitis B virus infection that had not been treated previously; because of severe hemodynamic compromise, only one MARS session was performed. The third patient had an initial diagnosis of acute liver failure and cryptogenic hepatitis, and was treated with five MARS sessions as a supportive measure until the definitive diagnosis (metastatic disease) was performed. In all patients, MARS therapy was well tolerated and induced only mild hypokalemia. In conclusion, although MARS therapy was an effective strategy for these cases of liver failure and greatly improved the biochemical variables, its impact on the mortality rate has not yet been determined.

REFERENCES

1. Popper H, Schaffner F. Progress in liver diseases. Philadelphia; London: Saunders; 1990.

2. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci. Sep 1991; 36(9): 1223-1228.

3. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg. Jan 1999; 5(1): 29-34.

4. Shakil AO, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. Mar 2000; 6(2):163-169.

5. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. Dec 17 2002; 137(12): 947-954.

6. Bernal W. Changing patterns of causation and the use of transplantation in the United kingdom. Semin Liver Dis. Aug 2003; 23(3): 227-237.

7. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology. Dec 1995; 109(6): 1907-1916.

8. Bihari DJ, Gimson AE, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis. May 1986; 6(2): 119-128.

9. Aggarwal S, Kramer D, Yonas H, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: a retrospective study. Hepatology. Jan 1994; 19(1): 80-87.

10. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. Mar 1999; 29(3): 648-653.

11. Lee WM. Acute liver failure in the United States. Semin Liver Dis. Aug 2003; 23(3): 217-226.

12. Baker A, Dhawan A, Devlin J, et al. Assessment of potential donors for living related liver transplantation. Br J Surg. Feb 1999; 86(2): 200-205.

13. Sen S, Williams R. New liver support devices in acute liver failure: a critical evaluation. Semin Liver Dis. Aug 2003; 23(3): 283-294.

14. Chiba T, Goto S, Yokosuka O, et al. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol. Feb 2004; 16(2): 225-228.

15. Cacopardo B, Nunnari G, Mughini MT, Tosto S, Benanti F, Nigro L. Fatal hepatitis during Epstein-Barr virus reactivation. Eur Rev Med Pharmacol Sci. Jul-Aug 2003; 7(4): 107-109.

16. Palanduz A, Yildirmak Y, Telhan L, et al. Fulminant hepatic failure and autoimmune hemolytic anemia associated with Epstein-Barr virus infection. J Infect. Aug 2002; 45(2): 96-98.

17. Chen SB, Zhang LL, Shi YF, Yang XL, Wang ZH. [Application of molecular adsorbents recirculating system in the treatment for liver failure of hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. Mar 2004; 12(3): 131-133.

18. Tan HK, Lim JS, Tan CK, et al. MARS therapy in critically ill patients with advanced malignancy: a clinical and technical report. Liver Int. 2003; 23 Suppl 3: 52-60.

19. Faybik P, Hetz H, Krenn CG, et al. Liver support in fulminant liver failure after hemorrhagic shock. Wien Klin Wochenschr. Sep 15 2003; 115(15-16): 595-598.

20. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. May 2000; 6(3): 277-286.

21. Heemann U, Treichel U, Loock J, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology. Oct 2002; 36(4 Pt 1): 949-958.

22. Sen S, Jalan R. The role of the Molecular Adsorbents Recirculating System (MARS) in the management of liver failure. Perfusion 2004; 19 Suppl 1: S43-48.

23. Sen S, Mookerjee RP, Davies NA, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther. Dec 2002; 16 Suppl 5: 32-38.